Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BetterLYF
Vancouver, British Columbia, Canadabetterlyf.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
BetterLife Pharma’s lead compound, BETR‑001 (2-bromo-LSD), is a non-hallucinogenic LSD derivative in preclinical/IND-enabling development for major depressive disorder and other neuropsychiatric conditions. Another candidate, BETR‑002 (dihydrohonokiol-B), targets anxiety-related disorders including benzodiazepine dependency and neurodegenerative diseases. Both are in preclinical or IND-enabling stages with no clinical results yet reported.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
None disclosed
Beyond the preview
Go deeper on BetterLYF.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BetterLYF.